Sex: M
Vaccine: COVID19, COVID19-2
Symptoms: COVID-19, Pain, SARS-CoV-2 test
Clinical narrative: just minor soreness; I was the first to have symptoms and subsequently tested positive i.e. 2/14/24/ I developed some minor symptoms and when I retested, I was again positive; This spontaneous case was reported by a non-health professional and describes the occurrence of PAIN (just minor soreness) and COVID-19 (I was the first to have symptoms and subsequently tested positive i.e. 2/14/24/ I developed some minor symptoms and when I retested, I was again positive) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. AS7143C and 045H22A) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (COMIRNATY) for an unknown indication.    Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose 1, Batch No.EN6200, Right arm, intramuscular use) on 22-Feb-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 2, Batch No.EN6208, Right arm, intramuscular use) on 23-Mar-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 3, Batch No.FC3184, Right arm, intramuscular use) on 24-Sep-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 4, Batch No.J87762, Right arm and intramuscular use) on 01-Apr-2022. Past adverse reactions to the above products included Pain with PFIZER BIONTECH COVID-19 VACCINE, PFIZER BIONTECH COVID-19 VACCINE, PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.   On 08-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular use) 1 dosage form. On 17-May-2023, received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular use) dosage was changed to 1 dosage form. On an unknown date, the patient received seventh dose of TOZINAMERAN (COMIRNATY) (Intramuscular use) 1 dosage form. On 14-Feb-2024,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced COVID-19 (I was the first to have symptoms and subsequently tested positive i.e. 2/14/24/ I developed some minor symptoms and when I retested, I was again positive). On an unknown date, the patient experienced PAIN (just minor soreness). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from February 2024 to February 2024 for COVID-19, at an unspecified dose and frequency. At the time of the report, PAIN (just minor soreness) outcome was unknown and COVID-19 (I was the first to have symptoms and subsequently tested positive i.e. 2/14/24/ I developed some minor symptoms and when I retested, I was again positive) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Feb-2024, SARS-CoV-2 test: Positive. In February 2024, SARS-CoV-2 test: Negative and Positive.         No concomitant medication was reported.  Reportedly, patient managed to avoid a COVID infection until this spring. Patient was first to have symptoms and subsequently tested positive. Soon after patient contacted his physician, had a virtual visit, and was prescribed Paxlovid. He subsequently completed the five-day course of treatment. His response to the treatment was quite good, symptoms much reduced within 24 hours. A day or so after finishing the drugs, he had virtually no symptoms, so he tested and was negative. A day or so later, he developed some minor symptoms and when retested, he was again positive.  The treatment markedly reduced the severity of symptoms for patient.   This case was linked to US-MODERNATX, INC.-MOD-2024-765995 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-765995:Same reporter, Wife case